GlaxoSmithKline’s HIV joint venture ViiV Healthcare could mount a challenge to Gilead’s HIV pre-exposure prophylaxis (PrEP) medicines after the FDA granted Breakthrough Therapy Designation
Author and journalist John-Manuel Andriote has spent much of his career writing about the impact of HIV/AIDS – a job that became much more personal when he himself was diagnosed in 2005.
The FDA has approved Rukobia, a first-in-class drug from ViiV Healthcare intended for older people with HIV, who have been on antiretroviral therapy (ART) for so long it is sta